{
    "eid": "2-s2.0-85134685335",
    "title": "Pharmacokinetics and Safety of WHO-Recommended Dosage and Higher Dosage of Levofloxacin for Tuberculosis Treatment in Children: a Pilot Study",
    "cover-date": "2022-09-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Microbiology (medical)",
            "@code": "2726",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Children",
        "Drug-resistant tuberculosis",
        "Isoniazid-resistant tuberculosis",
        "Levofloxacin",
        "Pharmacokinetics"
    ],
    "authors": [
        "Watsamon Jantarabenjakul",
        "Piyarat Suntarattiwong",
        "Noppadol Wacharachaisurapol",
        "Praon Supradish Na Ayudhya",
        "Weeraya Phaisal",
        "Monta Tawan",
        "Juthamanee Moonwong",
        "Tavitiya Sudjaritruk",
        "Pajaree Chariyavilaskul",
        "Thanyawee Puthanakit"
    ],
    "citedby-count": 1,
    "ref-count": 25,
    "ref-list": [
        "Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis",
        "Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers",
        "An HPLC method for levofloxacin determination and its application in biomedical analysis",
        "Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis",
        "The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920",
        "Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis",
        "Pharmacokinetics, safety, and dosing of novel pediatric levofloxacin dispersible tablets in children with multidrug-resistant tuberculosis exposure",
        "Pharmacokinetics of second-line antituberculosis drugs in children with multidrug-resistant tuberculosis in India",
        "Pharmacokinetics of levofloxacin in children treated for exposure to drug-resistant tuberculosis",
        "Pharmacokinetics and dosing of levofloxacin in children treated for active or latent multidrug-resistant tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands",
        "Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB",
        "Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders",
        "Safety concerns surrounding quinolone use in children",
        "Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis",
        "Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis",
        "In vitro susceptibility testing of levofloxacin and ofloxacin by microtiter plate Alamar blue against multidrug and non multidrug resistant Mycobacterium tuberculosis in Thailand",
        "Pediatric tuberculous meningitis: model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children",
        "Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability",
        "Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children",
        "Pharmacokinetics of levofloxacin in multidrug- and extensively drug-resistant tuberculosis patients",
        "Module 1: prevention: tuberculosis preventive treatment",
        "Module 4: treatment - drug-resistant tuberculosis treatment",
        "Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis",
        "Global and regional burden of isoniazid-resistant tuberculosis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60032250",
            "affilname": "Faculty of Medicine, Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032250",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "101618617",
            "affilname": "Queen Sirikit National Institute for Child Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/101618617",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Drug Safety Monitoring Board",
        "King Chulalongkorn Memorial Hospital",
        "Chulalongkorn University",
        "Khon Kaen University",
        "Health System Research Institute"
    ]
}